US Stock Dividends & Pharma Hub
US Stock Dividends & Pharma Hub focuses on US high-dividend blue chips and innovative pharma, daily updates on dividend announcements, FDA drug approvals, pharma M&A, pharma ETF trends, easy-to-understand, real-time news on dividends and pharma.
Singapore Exchange Real Estate Investment Trusts
Johnson & Johnson Double Good News: Dividend Raised 5% and FDA Approves New Drug, U.S. Stock Dividend Healthcare Presents Allocation Opportunity
Johnson & Johnson announced a 5% increase in its quarterly dividend to $1.26 per share, extending its over-60-year record of dividend growth; meanwhile, its blockbuster drug Tremfya received FDA approval for a new indication in ulcerative colitis. This article analyzes J&J's financial stability, dividend strategy, and innovative drug pipeline, discussing the allocation value and investment logic of the U.S. stock dividend healthcare sector in the current market environment.
Eli Lilly's weight loss drug Zepbound receives FDA priority review for new indication, driving strength in US dividend healthcare sector
Eli Lilly's Zepbound receives FDA priority review for new indication, expected to advance breakthrough in obesity with heart failure treatment. Combined with high dividend attribute, US dividend healthcare sector becomes new favorite for safe-haven funds, with pharmaceutical dividend and innovation dual-drive, industry valuation revaluation underway.
Singapore investment perspective: the game of 6G and satellite internet implementation
Singapore investment perspective on MWC Shanghai 2026: 6G shifts from 'what to do' to 'how to do', satellite internet enters scale networking and cost reduction phase, but terminals and capital returns remain to be verified.
GuocoLand issues S$110M notes at 2.5% coupon
GuocoLand plans to issue S$110M notes with a 2.5% coupon, issued by wholly-owned subsidiary GLL IHT and guaranteed, net proceeds for working capital.
Bank of Japan Rate Hike Fails to Halt Yen's Weakness
In late June 2024, the yen languished around 161.93 per dollar, and the Bank of Japan's rate hike to 1% failed to reverse the weakness. Communication between US and Japanese finance ministers signaled intervention, with the market watching for further yen-buying intervention. The article analyzes structural depreciation pressures on the yen and its future trajectory.
Brazil's Central Bank May Keep High Rates for a Prolonged Period to Tackle Inflation De-anchoring
Brazil's central bank released meeting minutes suggesting it may keep high interest rates for an extended period to address the risk of inflation de-anchoring. Affected by external factors such as the Middle East conflict, inflation expectations continue to rise, posing challenges to monetary policy.
Tensions in the Strait of Hormuz: Energy Security and Geopolitical Rivalry
Analyzing tensions in the Strait of Hormuz, exploring the impact of Iran's threats to close the strait on global energy supply and geopolitics, examining key factors in energy security and great power rivalry.
Goldman Sachs Warns: 50% Probability of Fed Rate Hike in July
Goldman Sachs warns of a 50% probability of a Fed rate hike in July, with new Chairman Warsh's hawkish debut catching the market off guard. The article analyzes the logic behind the rate hike, the impact of inflation data, and the policy shift's impact on asset prices and forward guidance.
US Stock Rally: Bubble or Revaluation?
This article analyzes the rally in US stocks since 2023 led by AI concepts, examining whether it is a bubble driven by technological frenzy or an asset revaluation driven by economic fundamentals, and discusses the impact on investors and the global economy.
